Objective:To investigate the expression of serum microRNA (miR)-195 in patients with esophageal cancer and its clinical significance.Methods:The clinical data of 105 patients with esophageal cancer in Beijing Huairou Hospital from April 2015 to April 2019 were retrospective analyzed. Ninety healthy examinees during the same period were selected as the healthy control. The relative expression level of serum miR-195 was detected by real-time quantitative fluorescence polymerase chain reaction. The receiver operating characteristic (ROC) curve was drawn, and the predictive value of serum miR-195 for esophageal cancer was analysis. Kaplan-Meier method was used for survival analysis, and log-rank test was used for comparison. Multivariate Cox analysis was used to analyze the independent risk factors of esophageal cancer prognosis.Results:The relative expression level of serum miR-195 in patients with esophageal cancer was significantly lower than that in healthy control (4.39 ± 1.86 vs. 7.17 ± 2.37), and there was statistical difference ( t = 9.155, P<0.05). The median level of serum miR-195 in patients with esophageal cancer was served as cut-off value.>4.39 was regarded as high expression (50 cases), and ≤ 4.39 was as low expression (55 cases). The relative expression level of serum miR-195 was related to tumor diameter, TNM stage, degree of invasion and lymph node metastasis ( P<0.05); however, there was no correlation with gender, age, pathological type and differentiation degree ( P>0.05). ROC curve analysis result showed that area under curve of serum miR-195 relative expression level in predicting esophageal cancer was 0.819 (95% CI 0.758 to 0.879, Z = 10.265, P<0.05), Yoden index was 0.539, and the optimal cut-off was 6.03, with a sensitivity of 82.86% and specificity of 71.11%. The median survival time in serum miR-195 low expression patients was significantly shorter than that in serum miR-195 high expression patients (25.7 months vs. 36.6 months), 5-year overall survival rate was significantly lower than that in serum miR-195 high expression patients (18.2% vs. 38.0%), and there were statistical differences ( P<0.05). Multivariate Cox analysis result showed that miR-195 and tumor diameter were independent risk factors for the prognosis of patients with esophageal cancer ( HR = 0.377 and 0.418, 95% CI 1.276 to 5.599 and 1.478 to 7.608, P<0.01). Conclusions:The relative expression of serum miR-195 in patients with esophageal cancer is significantly lower than that in healthy people. The lower the expression of miR-195, the worse the prognosis. The miR-195 can be used as one of the indicators for early prediction and prognostic evaluation of esophageal cancer.

Objective: To investigate the expression of carcinoembryonic antigen-related cell adhesion molecule 19 (CEACAM19) in colorectal cancer tissues, and evaluate the clinical pathological characters and prognostic significance. Methods: Ninety-eight patients with colorectal cancer in Beijing Huairou Hospital from July 2015 to July 2018 were selected. The expression level of CEACAM19 protein in primary colorectal cancer and corresponding non-tumor tissues (>2 cm) was detected by immunohistochemistry. The correlation between clinical pathological characters and CEACAM19 expression level was analyzed. The prognostic influencing factors were analyze by univariate and multivariate Cox regression methods. Survival curve was drawn by Kaplan-Meier method. Results: The high expression rate of CEACAM19 in colorectal cancer tissues was significantly higher than that in adjacent non-tumor tissues: 69.4% (68/98) vs. 16.3% (16/98), and there was statistical difference (χ² = 45.060; P<0.01). Expression of CEACAM19 in colorectal cancer tissues was significantly associated with TNM stage (P<0.05), and was not associated with age, gender, tumor diameter, histological differentiation, tumor location, lymph node stage and invasion depth (P>0.05). Univariate Cox regression analysis result showed that lymph node stage, TNM stage and CEACAM19 expression were influencing factors of overall survival in patients with colorectal cancer (P<0.05 or <0.01), and the TNM stage and CEACAM19 expression were influencing factors of disease-free survival in patients with colorectal cancer (P<0.01). Multivariate Cox regression analysis result showed that TNM stage increased and CEACAM19 high expression were independent risk factors of overall survival (HR = 2.628 and 0.199, 95% CI 1.147 to 6.021 and 0.045 to 0.868, P = 0.022 and 0.032) and disease-free survival (HR = 2.009 and 0.303, 95% CI 0.965 to 4.185 and 0.101 to 0.911, P = 0.048 and 0.034) in patients with colorectal cancer. Survival curve analysis result showed that the median overall survival and disease-free survival in CEACAM19 low expression patients were significantly longer than CEACAM19 high expression patients (47.9 months vs. 27.8 months and 43.2 months vs. 26.3 months, P<0.01); the median overall survival and disease-free survival in TNM Ⅰ to Ⅱ stage were significantly longer than TNM Ⅲ stage patients (43.9 months vs. 24.2 months and 39.3 months vs. 23.7 months, P<0.01). Conclusions The CEACAM19 in colorectal cancer tissues is high expression, and the CEACAM19 expression level can be used as biomarker for prediction the prognosis of colorectal cancer.